THERAPY DOSSIER · th-757bb5b54e28

Ex vivo engineered bone marrow-derived immature dendritic cells, lentivirally transduced and loaded with therapeutic cargo

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23613937 ↗2013Mixed findings

Derivation of injury-responsive dendritic cells for acute brain targeting and therapeutic protein delivery in the stroke-injured rat.

RatIschaemia-reperfusionCerebral (MCAO/stroke)Intracarotid infusionThree hours after transient middle cerebral artery occlusion

Model: Transient middle cerebral artery occlusion (tMCAO) ischaemic stroke

Cultured immature dendritic cells homed transiently and selectively to the injured hemisphere, persisting at 3 h and gone by 24 h, with 2 to 3 per cent of radiolabelled cells at the injured side of the head, and cells loaded with therapeutic cargo suppressed initial neuron death.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…